Not Signed In -
Efalizumab |
Raptiva |
Clinical Trial: A Study to Evaluate the Safety of Raptiva in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g
This study is no longer recruiting patients.
|
Purpose
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Psoriasis | Drug: Raptiva (efalizumab) | Phase III |
MedlinePlus related topics: Psoriasis
Study Type: Interventional
Study Design: Treatment, Open Label, Safety Study
Official Title: An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g
Eligibility
Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Signed informed consent
- Previous participation in Study ACD2600g
- For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study
Exclusion Criteria:
- Any medical condition that, in the judgment of the investigator, would jeopardize the subject’s safety following exposure to Efalizumab
More Information
Study ID Numbers: ACD2601g
Record last reviewed: November 2004
Last Updated: November 12, 2004
Record first received: November 12, 2004
ClinicalTrials.gov Identifier: NCT00096603
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: November 2004
Last Updated: November 12, 2004
Record first received: November 12, 2004
ClinicalTrials.gov Identifier: NCT00096603
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Efalizumab (Drug Digest)
- Raptiva (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
